Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes

[1]  T. Vilsbøll,et al.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.

[2]  E. Sinakos,et al.  Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? , 2018, World journal of hepatology.

[3]  Toshihiro Kobayashi,et al.  Angiotensin II induces cholesterol accumulation and impairs insulin secretion by regulating ABCA1 in beta cells[S] , 2018, Journal of Lipid Research.

[4]  Y. Ahn,et al.  Prolactin regulatory element-binding (PREB) protein regulates hepatic glucose homeostasis. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[5]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[6]  A. Diehl,et al.  Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis , 2017, The New England journal of medicine.

[7]  K. Cusi,et al.  Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option , 2017, Journal of Investigative Medicine.

[8]  L. Ye,et al.  Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus , 2017, Medicine.

[9]  S. Sato,et al.  Prolactin regulatory element-binding protein is involved in suppression of the adiponectin gene in vivo , 2017, Journal of Endocrinological Investigation.

[10]  K. Cusi,et al.  Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action , 2017, Diabetes Care.

[11]  J. Fonseca,et al.  Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". , 2017, Journal of hepatology.

[12]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[13]  R. Spang,et al.  Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients. , 2016, Gastroenterology.

[14]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[15]  R. Wei,et al.  Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner. , 2016, American journal of physiology. Endocrinology and metabolism.

[16]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[17]  S. Ichinose,et al.  Prolactin Regulatory Element Binding Protein Is Involved in Hepatitis C Virus Replication by Interaction with NS4B , 2016, Journal of Virology.

[18]  A. Gastaldelli,et al.  The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis , 2015, Nutrients.

[19]  K. Rajapakshe,et al.  The camKK2/camKIV relay is an essential regulator of hepatic cancer , 2015, Hepatology.

[20]  Mary E Rinella,et al.  Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.

[21]  R. Kleemann,et al.  Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology , 2014, PloS one.

[22]  Do Yeon Kim,et al.  Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway. , 2014, Biological & pharmaceutical bulletin.

[23]  M. Hayden,et al.  Hepatic ABCA1 Expression Improves β-Cell Function and Glucose Tolerance , 2014, Diabetes.

[24]  Xin-chun Yang,et al.  Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. , 2013, Arquivos brasileiros de endocrinologia e metabologia.

[25]  Won-Young Lee,et al.  GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease , 2012, Diabetes & metabolism journal.

[26]  Soonkyu Chung,et al.  Hepatic ABCA1 and VLDL triglyceride production. , 2012, Biochimica et biophysica acta.

[27]  Gang Wang,et al.  A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay development , 2012, Cytotechnology.

[28]  J. Ayala,et al.  Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice. , 2012, American journal of physiology. Endocrinology and metabolism.

[29]  H. Iwama,et al.  Exendin-4 regulates the expression of the ATP-binding cassette transporter A1 via transcriptional factor PREB in the pancreatic β cell line , 2011, Journal of endocrinological investigation.

[30]  T. Ishida,et al.  Transcriptional factor prolactin regulatory element-binding protein-mediated gene transcription of ABCA1 via 3',5'-cyclic adenosine-5'-monophosphate. , 2010, Atherosclerosis.

[31]  H. Pijl,et al.  GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. , 2010, American journal of physiology. Endocrinology and metabolism.

[32]  F. Anania,et al.  Glucagon‐like peptide‐1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway , 2010, Hepatology.

[33]  M. Hayden,et al.  Targeted Deletion of Hepatocyte ABCA1 Leads to Very Low Density Lipoprotein Triglyceride Overproduction and Low Density Lipoprotein Hypercatabolism* , 2010, The Journal of Biological Chemistry.

[34]  S. Klein,et al.  Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications , 2010, Hepatology.

[35]  H. Iwama,et al.  Hyperglycemia suppresses ABCA1 expression in vascular smooth muscle cells. , 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[36]  T. Ishida,et al.  The transcriptional factor PREB mediates MCP-1 transcription induced by cytokines in human vascular endothelial cells. , 2009, Atherosclerosis.

[37]  H. Tokumitsu,et al.  Exendin-4 regulates pancreatic ABCA1 transcription via CaMKK/CaMKIV pathway , 2009, Journal of cellular and molecular medicine.

[38]  H. Tokumitsu,et al.  Exendin‐4 regulates glucokinase expression by CaMKK/CaMKIV pathway in pancreatic β‐cell line , 2009, Diabetes, obesity & metabolism.

[39]  T. Ishida,et al.  Human scavenger receptor class b type 1 is regulated by activators of peroxisome proliferators-activated receptor-γ in hepatocytes , 2009, Endocrine.

[40]  M. Hayden,et al.  Cholesterol in islet dysfunction and type 2 diabetes. , 2008, The Journal of clinical investigation.

[41]  N. Wong,et al.  Interferon α decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes , 2007, Gut.

[42]  T. Ishida,et al.  Pancreatic glucokinase is activated by insulin-like growth factor-I. , 2007, Endocrinology.

[43]  James D. Johnson,et al.  β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment , 2007, Nature Medicine.

[44]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[45]  N. Wong,et al.  Prolactin regulatory element binding protein as a potential transcriptional factor for the insulin gene in response to glucose stimulation , 2006, Diabetologia.

[46]  F. Anania,et al.  Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice , 2006, Hepatology.

[47]  H. Tokumitsu,et al.  The role of calcium/calmodulin-dependent protein kinase cascade in glucose upregulation of insulin gene expression. , 2004, Diabetes.

[48]  M. Hayden,et al.  Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1 Published, JLR Papers in Press, May 1, 2003. DOI 10.1194/jlr.M300110-JLR200 , 2003, Journal of Lipid Research.

[49]  H. Brewer,et al.  Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations Published, JLR Papers in Press, November 4, 2002. DOI 10.1194/jlr.M200414-JLR200 , 2003, Journal of Lipid Research.

[50]  G. Frost,et al.  Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. , 2001, American journal of physiology. Endocrinology and metabolism.

[51]  S. Toyokuni,et al.  Activating transcription factor-2 is a positive regulator in CaM kinase IV-induced human insulin gene expression. , 2000, Diabetes.

[52]  P. M. Hinkle,et al.  Expression cloning and characterization of PREB (prolactin regulatory element binding), a novel WD motif DNA-binding protein with a capacity to regulate prolactin promoter activity. , 1999, Molecular endocrinology.

[53]  C. Kane,et al.  Ca 2+ /Calmodulin-dependent protein kinase IV and calcium signaling , 1998, Biometals.

[54]  T. Soderling,et al.  Activation of Ca2+/Calmodulin-dependent Protein Kinase (CaM-kinase) IV by CaM-kinase Kinase in Jurkat T Lymphocytes (*) , 1995, The Journal of Biological Chemistry.

[55]  C. Fielding,et al.  Molecular physiology of reverse cholesterol transport. , 1995, Journal of lipid research.

[56]  A. Means,et al.  Calcium/calmodulin-dependent protein kinase types II and IV differentially regulate CREB-dependent gene expression , 1994, Molecular and cellular biology.

[57]  T. Soderling,et al.  Characterization of Ca2+/calmodulin-dependent protein kinase IV. Role in transcriptional regulation. , 1994, The Journal of biological chemistry.

[58]  R. Fisher,et al.  Nuclear and axonal localization of Ca2+/calmodulin-dependent protein kinase type Gr in rat cerebellar cortex. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[59]  A. Tall.  Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. , 1990, The Journal of clinical investigation.

[60]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[61]  C. Streutker,et al.  GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. , 2013, Endocrinology.

[62]  H. Iwama,et al.  17β-Estradiol regulates scavenger receptor class BI gene expression via protein kinase C in vascular endothelial cells , 2013, Endocrine.

[63]  宮井 由美.  Exendin-4 regulates the expression of the ATP-binding cassette transporter A1 via transcriptional factor PREB in the pancreatic β cell line , 2011 .

[64]  T. Ishida,et al.  Calcium/calmodulin-dependent protein kinase IV involvement in the pathophysiology of glucotoxicity in rat pancreatic β-cells. , 2011, Metabolism: clinical and experimental.